Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MSCI Germany (DAX) (EWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares MSCI Germany (DAX) — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $279.77 (market cap $39.89B), while iShares MSCI Germany (DAX) trades at $41.38. The key difference: iShares MSCI Germany (DAX) is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWG | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $44.56 |
52-Week Low | $278.09 | $38.08 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EWG trades at $41.49, down slightly by 0.12% today, with technical indicators showing a bearish bias from moving averages and mixed signals from oscillators. Key financial ratios are unavailable in the provided data, and the stock faces headwinds from European economic policies and interest rate changes. Recent news highlights German healthcare reforms and ECB rate hikes impacting market sentiment.
The outlook for EWG is cautious due to bearish technicals and macroeconomic pressures in Europe. Investment opportunities may arise from potential short squeezes noted by Citi, but risks include regulatory changes and energy cost volatility. Investors should monitor ECB policy shifts and German economic indicators for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →
